SCZD3
MCID: SCH080
MIFTS: 32

Schizophrenia 3 (SCZD3)

Categories: Genetic diseases, Mental diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Schizophrenia 3

MalaCards integrated aliases for Schizophrenia 3:

Name: Schizophrenia 3 56 12 15 71
Schizophrenia Susceptibility Locus, Chromosome 6-Related 56 13
Sczd3 56 12
Schizophrenia 3 with or Without an Affective Disorder 56

Characteristics:

OMIM:

56
Inheritance:
autosomal dominant susceptibility (6p23)


HPO:

31
schizophrenia 3:
Inheritance autosomal dominant inheritance


Classifications:



External Ids:

Disease Ontology 12 DOID:0070079
OMIM 56 600511
MedGen 41 C1838069
UMLS 71 C1838069

Summaries for Schizophrenia 3

Disease Ontology : 12 A schizophrenia that has material basis in an autosomal dominant mutation of SCZD3 on chromosome 6p23.

MalaCards based summary : Schizophrenia 3, also known as schizophrenia susceptibility locus, chromosome 6-related, is related to schizophrenia and alzheimer disease. An important gene associated with Schizophrenia 3 is SCZD3 (Schizophrenia Disorder 3). The drugs Naltrexone and Bupropion have been mentioned in the context of this disorder. Affiliated tissues include brain, cortex and prefrontal cortex, and related phenotypes are schizophrenia and abnormality of the nervous system

More information from OMIM: 600511

Related Diseases for Schizophrenia 3

Graphical network of the top 20 diseases related to Schizophrenia 3:



Diseases related to Schizophrenia 3

Symptoms & Phenotypes for Schizophrenia 3

Human phenotypes related to Schizophrenia 3:

31
# Description HPO Frequency HPO Source Accession
1 schizophrenia 31 HP:0100753
2 abnormality of the nervous system 31 HP:0000707

Symptoms via clinical synopsis from OMIM:

56
Neuro:
schizophrenia

Clinical features from OMIM:

600511

Drugs & Therapeutics for Schizophrenia 3

Drugs for Schizophrenia 3 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 44)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Naltrexone Approved, Investigational, Vet_approved Phase 4 16590-41-3 5360515
2
Bupropion Approved Phase 4 34911-55-2, 34841-39-9 444
3
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
4
Ethanol Approved Phase 4 64-17-5 702
5 Dopamine Antagonists Phase 4
6 Antipsychotic Agents Phase 4
7 Paliperidone Palmitate Phase 4
8 Dopamine Agents Phase 4
9 Cytochrome P-450 Enzyme Inhibitors Phase 4
10 Antidepressive Agents Phase 4
11 Narcotics Phase 4
12 Psychotropic Drugs Phase 4
13 Narcotic Antagonists Phase 4
14
Serotonin Investigational, Nutraceutical Phase 4 50-67-9 5202
15
Rimonabant Approved, Investigational Phase 2 158681-13-1, 168273-06-1 104850
16 Neurotransmitter Agents Phase 2
17 Hormones Phase 2
18 Anti-Obesity Agents Phase 2
19 Hormone Antagonists Phase 2
20
leucovorin Approved 58-05-9 6006 143
21
Methylcobalamin Approved, Investigational 13422-55-4
22
Hydroxocobalamin Approved 13422-51-0 15589840 11953898
23
Nicotinamide Approved, Investigational 98-92-0 936
24
Guaifenesin Approved, Investigational, Vet_approved 93-14-1 3516
25
Folic acid Approved, Nutraceutical, Vet_approved 59-30-3 6037
26
Cyanocobalamin Approved, Nutraceutical 68-19-9 44176380
27
Niacin Approved, Investigational, Nutraceutical 59-67-6 938
28
Cobalamin Experimental 13408-78-1 6857388
29 Trace Elements
30 Micronutrients
31 Vitamins
32 Vitamin B Complex
33 Vitamin B 12
34 Hematinics
35 Vitamin B12
36 Nutrients
37 Folate
38 Vitamin B9
39 Nicotinic Acids
40 Vitamin B3
41 Acidophilus
42 Chlorpheniramine, phenylpropanolamine drug combination
43 Bifidobacterium
44
Arginine Investigational, Nutraceutical 74-79-3 6322

Interventional clinical trials:

(show all 17)
# Name Status NCT ID Phase Drugs
1 A Study on the Efficacy, Pharmacokinetics and Adverse Effects of Paliperidone ER Unknown status NCT02433717 Phase 4 Paliperidone ER
2 Effect of Naltrexone and Bupropion Combination on Weight Loss and Smoking Cessation in Obese, Cigarette-smoking Patients With Schizophrenia Completed NCT02736474 Phase 4 Naltrexone;Placebo Naltrexone;Bupropion;Placebo Bupropion
3 A Double-blind Placebo Controlled Trial the Comparison of Effectiveness of Repetitive TMS and iTBS on Negative Symptoms and Cognition in Patients With Schizophrenia Unknown status NCT01315587 Phase 2
4 A Culturally Based Family Therapy for Schizophrenia Completed NCT00356317 Phase 2
5 The Effects of the Cannabinoid-1 Receptor Antagonist, Rimonabant, on Weight and Metabolic Risk Factors in People With Schizophrenia Terminated NCT00547118 Phase 2 Rimonabant;Placebo
6 9 wk, Randomized, 2-blind, Placebo-controlled, 2X2 Cross-over Phase 1 Study of 25 mg of Scelectium Tortuosum (as Zembrin®) in Aged Normals to Find Effects on Mental, Emotional and Cognitive Safety Measures and Cytokines. Completed NCT01805518 Phase 1
7 Relationships of One-carbon Cycle Pathway With Psychopathology and Metabolic Abnormalities in Patients With Schizophrenia and Potential Intervention Strategy With Folic Acid and Vitamin B12 Unknown status NCT02916121
8 Specific Cognitive Remediation for Schizophrenia (RECOS) and Sheltered Employment: a Multicentre Controlled Randomized Trial. Completed NCT01891929
9 A Randomised, Double-blind, Cross-over, Placebo Controlled, Adjunctive-treatment of L-arginine Added to Treatment-as-usual (TAU) in Schizophrenia Completed NCT00718510 L-Arginine
10 Gender Differences in Social Cognition in Patients With Schizophrenia of Recent Diagnosis and Healthy Controls Subjects Completed NCT02575209
11 Molecular Genetic Study of Schizophrenia: Parent-Offspring Trios Completed NCT00155506
12 Shiatsu Adjuvant Therapy for Hospitalized Psychiatric Patients: an Open Pilot Study Completed NCT00425399
13 A Positional Cloning Study on Schizophrenia Completed NCT00155649
14 Transcranial Direct Current Stimulation (tDCS) Studies of Cognition, Oscillations and GABA Levels in Schizophrenia Recruiting NCT04267003
15 A 12-weeks Study to Evaluate the Dietary Fiber and Probiotics Treatment in Prevention and Intervention of Weight-gain and Cognitive Impairment of Schizophrenia or Bipolar Disorder Recruiting NCT03379597 Bifico (Live combined bifidobacterium,Lactobacillus and Enterococcus capsules, Oral)
16 A Study of the Aggressive Acts Among Patients With Schizophrenia Suspended NCT00172497
17 A Study on Etiological Factors of Schizophrenia Terminated NCT00155636

Search NIH Clinical Center for Schizophrenia 3

Genetic Tests for Schizophrenia 3

Anatomical Context for Schizophrenia 3

MalaCards organs/tissues related to Schizophrenia 3:

40
Brain, Cortex, Prefrontal Cortex, Eye, Cerebellum, Lung, Thyroid

Publications for Schizophrenia 3

Articles related to Schizophrenia 3:

(show top 50) (show all 136)
# Title Authors PMID Year
1
Schizophrenia risk from complex variation of complement component 4. 56
26814963 2016
2
Common variants on chromosome 6p22.1 are associated with schizophrenia. 56
19571809 2009
3
Common variants conferring risk of schizophrenia. 56
19571808 2009
4
Common polygenic variation contributes to risk of schizophrenia and bipolar disorder. 56
19571811 2009
5
Systematic meta-analyses and field synopsis of genetic association studies in schizophrenia: the SzGene database. 56
18583979 2008
6
Assessment of cumulative evidence on genetic associations: interim guidelines. 56
17898028 2008
7
Impaired glutathione synthesis in schizophrenia: convergent genetic and functional evidence. 56
17921251 2007
8
Analysis of high-resolution HapMap of DTNBP1 (Dysbindin) suggests no consistency between reported common variant associations and schizophrenia. 56
17033966 2006
9
Dysbindin genotype and negative symptoms in schizophrenia. 56
16513878 2006
10
Identifying potential risk haplotypes for schizophrenia at the DTNBP1 locus in Han Chinese and Scottish populations. 56
16044171 2005
11
Genetic evidence for a distinct subtype of schizophrenia characterized by pervasive cognitive deficit. 56
16080121 2005
12
Haplotypes at the dystrobrevin binding protein 1 (DTNBP1) gene locus mediate risk for schizophrenia through reduced DTNBP1 expression. 56
15917270 2005
13
Evidence of novel neuronal functions of dysbindin, a susceptibility gene for schizophrenia. 56
15345706 2004
14
Association of the DTNBP1 locus with schizophrenia in a U.S. population. 56
15362017 2004
15
Linkage disequlibrium in the DTNBP1 (dysbindin) gene region and on chromosome 1p36 among psychotic patients from a genetic isolate in Israel: findings from identity by descent haplotype sharing analysis. 56
15211634 2004
16
Identification in 2 independent samples of a novel schizophrenia risk haplotype of the dystrobrevin binding protein gene (DTNBP1). 56
15066891 2004
17
The DTNBP1 (dysbindin) gene contributes to schizophrenia, depending on family history of the disease. 56
14618545 2003
18
Support for association of schizophrenia with genetic variation in the 6p22.3 gene, dysbindin, in sib-pair families with linkage and in an additional sample of triad families. 56
12474144 2003
19
Genetic variation in the 6p22.3 gene DTNBP1, the human ortholog of the mouse dysbindin gene, is associated with schizophrenia. 56
12098102 2002
20
Genome-wide scans of three independent sets of 90 Irish multiplex schizophrenia families and follow-up of selected regions in all families provides evidence for multiple susceptibility genes. 56
12140777 2002
21
Association analysis of NOTCH4 loci in schizophrenia using family and population-based controls. 56
11381257 2001
22
Failure to confirm NOTCH4 association with schizophrenia in a large population-based sample from Scotland. 56
11381258 2001
23
The NOTCH4 locus is associated with susceptibility to schizophrenia. 56
10932176 2000
24
NIMH Genetics Initiative Millenium Schizophrenia Consortium: linkage analysis of African-American pedigrees. 56
9674972 1998
25
Fine mapping of 39 ESTs on human chromosome 6p23-p25. 56
9417921 1997
26
Use of a quantitative trait to map a locus associated with severity of positive symptoms in familial schizophrenia to chromosome 6p. 56
9399881 1997
27
6p24-22 region and major psychoses in the Eastern Quebec population. Le Groupe IREP. 56
9184316 1997
28
Linkage study of chromosome 6p in sib-pairs with schizophrenia. 56
9184317 1997
29
Linkage analyses of schizophrenia to chromosome 6p24-p22: an attempt to replicate. 56
8950418 1996
30
Additional support for schizophrenia linkage on chromosomes 6 and 8: a multicenter study. Schizophrenia Linkage Collaborative Group for Chromosomes 3, 6 and 8. 56
8950417 1996
31
Evidence of linkage disequilibrium between schizophrenia and the SCa1 CAG repeat on chromosome 6p23. 56
8751875 1996
32
Irish study on high-density schizophrenia families: field methods and power to detect linkage. 56
8723045 1996
33
An international two-stage genome-wide search for schizophrenia susceptibility genes. 56
7581457 1995
34
Genetic dissection of complex traits: guidelines for interpreting and reporting linkage results. 56
7581446 1995
35
A potential vulnerability locus for schizophrenia on chromosome 6p24-22: evidence for genetic heterogeneity. 56
7581452 1995
36
Evaluation of a susceptibility gene for schizophrenia on chromosome 6p by multipoint affected sib-pair linkage analysis. 56
7581458 1995
37
Dispute splits schizophrenia study. 56
7754362 1995
38
Evidence for a susceptibility locus for schizophrenia on chromosome 6pter-p22. 56
7647789 1995
39
Safety and clinical effectiveness of Withania Somnifera (Linn.) Dunal root in human ailments. 61
32201301 2020
40
Outpatient Anesthesia Facilitates Stereotactic Body Radiation Therapy for Early Stage Lung Cancer Patients With Advanced Cognitive Impairments. 61
32529139 2020
41
Exploring how a genetic attribution to disease relates to stigma experiences of Xhosa patients with schizophrenia in South Africa. 61
32409883 2020
42
The COVID-19 Global Pandemic: Implications for People With Schizophrenia and Related Disorders. 61
32343342 2020
43
Functioning in community-dwelling patients with schizophrenia spectrum disorders in rural Greece. 61
31692402 2020
44
Comprehensive review of the research employing the schizophrenia cognition rating scale (SCoRS). 61
31196736 2019
45
Cerebrospinal fluid markers of inflammation and infections in schizophrenia and affective disorders: a systematic review and meta-analysis. 61
30116031 2019
46
The relationship between the alterations in metabolite levels in the dorsolateral prefrontal cortex and clinical symptoms of patients with first-episode schizophrenia: a one year follow-up study. 61
30728911 2019
47
Performance of International Medical Students In psychosocial medicine. 61
28693486 2017
48
[Evolution of the schizophrenic deficit concept]. 61
29053114 2017
49
The 40-Hz Auditory Steady-State Response in Patients With Schizophrenia: A Meta-analysis. 61
27732692 2016
50
What are the top 10 physical activity research questions in schizophrenia? 61
26728764 2016

Variations for Schizophrenia 3

Expression for Schizophrenia 3

Search GEO for disease gene expression data for Schizophrenia 3.

Pathways for Schizophrenia 3

GO Terms for Schizophrenia 3

Sources for Schizophrenia 3

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....